Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study
United European Gastroenterology Journal · 2023-06 · 11 (5) · 458-470
DOI: 10.1002/ueg2.12397 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 07.05.2023. Verfasst von Katharina Sophie Seeling und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, RWTH Aachen University, Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen.
Abstract (Originalsprache)
Background
Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete.
Objective
To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality.
Methods
We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed ( n = 20,603) and ICD‐10 diagnosed ( n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients.
Results
In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]).
Conclusion
Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
- Department of Biobehavioral Health Sciences, Perelman School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany.
- Institute for Translational Psychiatry, University of Münster, Münster, Germany.
- Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.
- The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Katharina Sophie Seeling, Kate Townsend Creasy, Daniel Keszthelyi, Carolin Victoria Schneider
Förderung
- Bundesministerium für Bildung und Forschung
- RWTH Aachen University
- Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
Zitieren
APA
Seeling, K. S., Hehl, L., Vell, M. S., Rendel, M. D., Creasy, K. T., Trautwein, C., Mehler, D. M. A., Keszthelyi, D., Schneider, K. M., & Schneider, C. V. (2023). Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study. United European Gastroenterology Journal, 11(5), 458-470. https://doi.org/10.1002/ueg2.12397
Vancouver
Seeling KS, Hehl L, Vell MS, Rendel MD, Creasy KT, Trautwein C, et al. Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study. United European Gastroenterology Journal. 2023;11(5):458-470. doi:10.1002/ueg2.12397
BibTeX
@article{Seeling2023,
author = {Seeling, Katharina Sophie and Hehl, Leonida and Vell, Mara Sophie and Rendel, Miriam Daphne and Creasy, Kate Townsend and Trautwein, Christian and Mehler, David Marc Anton and Keszthelyi, Daniel and Schneider, Kai Markus and Schneider, Carolin Victoria},
title = {Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: A phenome‐wide association study},
journal = {United European Gastroenterology Journal},
year = {2023},
volume = {11},
number = {5},
pages = {458--470},
doi = {10.1002/ueg2.12397}
}
EUVIMED